Canadian cannabis giant Organigram has officially rebranded as it pivots its strategy towards international operations.
The newly dubbed Organigram Global says its rebrand signifies its evolution from a regional medical and recreational cannabis producer to a globally focused multi-country operator (MCO).
On the surface, the rebrand includes an overhauled visual identity across its various brands, but the company will retain its OGI ticker on the TSX and NASDAQ stock exchanges.
Looking below the surface, its refreshed identity positions Organigram Global to capitalize on opportunities outside of its native Canada, and according to its SVP of Global Brands Megan McCrae, ‘bring the best of Canadian cannabis to the world’.
It highlighted its international footprint in Germany via Sanity Group and says it expects to receive EU-GMP certification in the coming months, opening the door to the rest of Europe, where it plans to scale exports in due course.
Closer to home, Organigram is also targeting the vast US market, having made two key investments in Open Book Extracts and Phylos Bioscience, enabling it to take part in the world’s largest cannabis market.
The company continues to export Canadian-grown cannabis to markets including Germany, the UK, and Australia, with plans to increase shipment volumes in 2025.
Organigram is also benefiting from a strategic investment fund dubbed Jupiter, made possible by a follow-on investment from British American Tobacco (BAT). Jupiter is expected to fuel further international growth through targeted investments and partnerships.
“As Organigram has grown from its roots in Atlantic Canada to become a global player, our identity needed to evolve alongside our business,” said CEO Beena Goldenberg.
“We are exporting premium products, expanding into international markets, and shaping the future of the cannabis industry.”
